Filing Flows › Comparisons › LNAI vs ALT
Lunai Bioworks vs Altimmune: LNAI and ALT compared
Lunai Bioworks is the larger company: $31K of revenue in its latest quarter (Q4 FY26) against $26K for Altimmune (Q4 2025).
Where the money goes: LNAI and ALT
Lunai Bioworks (LNAI) · Q4 FY26
Lunai Bioworks, Q4 FY26: revenue $31K, net loss $2.0M, operating cash flow −$1.8M. The chart follows the revenue to costs, profit and cash.
Altimmune (ALT) · Q4 2025
Altimmune, Q4 2025: revenue $26K (+420% year over year), net loss $27.4M, operating cash flow −$19.4M. The chart follows the revenue to costs, profit and cash.
| Lunai Bioworks (LNAI) | Altimmune (ALT) | |
|---|---|---|
| Latest quarter | Q4 FY26 | Q4 2025 |
| Revenue | $31K | $26K |
| Revenue growth, Y/Y | — | +420% |
| Operating margin | n/m | n/m |
| Net earnings | −$2.0M | −$27.4M |
| Operating cash flow | −$1.8M | −$19.4M |
Questions
Which is bigger, Lunai Bioworks or Altimmune?
Lunai Bioworks is the larger company: $31K of revenue in its latest quarter (Q4 FY26) against $26K for Altimmune (Q4 2025).
More: Lunai Bioworks earnings · how Lunai Bioworks makes money · Altimmune earnings · how Altimmune makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Oct 13, 2026; 10-K filed Mar 6, 2026). Fiscal quarters can end on different dates. Not investment advice.